1052713-47-9 Usage
General Description
Tert-butyl N-[(3R,4R)-4-fluoropiperidin-3-yl]carbamate is a synthetic chemical compound with the molecular formula C11H20FN3O2. It is a carbamate derivative that contains a tert-butyl group and a piperidine ring with a fluorine substituent in the 4-position. tert-butyl N-[(3R,4R)-4-fluoropiperidin-3-yl]carbamate is commonly used in medicinal chemistry and drug development as a building block for the synthesis of pharmaceutical compounds, especially those targeting the central nervous system. Additionally, its unique structure and properties make it a valuable tool in studying the biological activity and pharmacological effects of related compounds. However, tert-butyl N-[(3R,4R)-4-fluoropiperidin-3-yl]carbamate should be handled and used with proper safety precautions due to its potential for hazardous or toxic effects if mishandled.
Check Digit Verification of cas no
The CAS Registry Mumber 1052713-47-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,2,7,1 and 3 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1052713-47:
(9*1)+(8*0)+(7*5)+(6*2)+(5*7)+(4*1)+(3*3)+(2*4)+(1*7)=119
119 % 10 = 9
So 1052713-47-9 is a valid CAS Registry Number.
1052713-47-9Relevant articles and documents
Bicyclic Kinase Inhibitors
-
Page/Page column 32-33, (2011/08/22)
New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
Pim kinase inhibitors and methods of their use
-
Page/Page column 14, (2010/09/05)
The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
